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ABSTRACT
We analysed if levels of four miRNAs would change after a lifestyle intervention involving dietary 
and exercises in prediabetes. MiRNAs previously shown to be associated with diabetes (Let-7a, 
Let-7e, miR-144 and miR-92a) were extracted from serum pre- and post-intervention. mRNA was 
extracted from fat-tissue for gene expression analyses. The intervention resulted in increased Let- 
7a and miR-92a. We found correlations between miRNAs and clinical variables (triglycerides, 
cholesterol, insulin, weight and BMI). We also found correlations between miRNAs and target 
genes, revealing a link between miR-92a and IGF system. A lifestyle intervention resulted in 
marked changes in miRNAs. The association of miRNAs with insulin and the IGF system (both 
receptors and binding proteins) may represent a mechanism of regulating IGFs metabolic actions.
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Introduction
Impaired glucose regulation (IGR) refers to a metabolic 
state between normal glucose homoeostasis and diabetes 
[1]. Usually referred as pre-diabetes or non-diabetic 
hyperglycaemia, IGR represents a high risk to develop 
type 2 diabetes mellitus (T2DM). T2DM is thought to 
arise from a summation of genetic and environmental/ 
epigenetic factors, which result in a decline in insulin 
activity, followed by a chronic pancreatic beta-cell dys-
function. Diverse circulating microRNAs (miRNAs) have 
been identified as being significantly different between 
T2DM patients and IGR individuals [2,3].
MiRNAs are endogenous, 21–25 nucleotides in 
length, small non-coding RNA molecules that regulate 
gene expression at the post-transcriptional level by 
binding to target mRNAs and affecting their translation 
[4]. MiRNAs participate in a variety of important bio-
logical processes including gene regulation, prolifera-
tion, apoptosis and metabolism [5,6]. Because miRNAs 
are relatively stable in plasma and are regulated in 
health and disease conditions, they are increasingly 
being used as a new class of disease biomarkers [7].
Dysfunction of miRNAs significantly contributes to 
initiation and progression of T2DM. The investigation 
surrounding miRNAs has grown considerably, and it 
has been demonstrated that they have functional roles 
in insulin secretion, glucose homoeostasis and 
adipocyte differentiation [8–10]. Additionally, circulat-
ing miRNAs have been shown to be involved in the 
mechanisms underlying cardiovascular disease (CVD) 
[10–12], being CVD the main cause of mortality in 
T2DM people, affecting at least 68% of these indivi-
duals who are 65 y or older [13]. In plasma, they are 
protected from circulating ribonucleases through their 
association with lipid and protein carriers [14]. 
Lipoproteins, high-density lipoproteins (HDL) and 
low-density lipoproteins (LDL) were reported to trans-
port miRNAs [15]. In the last decade, many miRNAs 
have been identified to play a pathophysiological role in 
T2DM, among them, Let-7a has been associated with 
glucose metabolism [16,17], Let-7e showed sensitivity 
to metformin treatment [18], miR-144 was demon-
strated to play a role in beta-cell dysfunction [19] and 
insulin signalling [19]; and miR-92a associated with cell 
dysfunction in T2DM [20], endothelial dysfunction 
[21,22], and coronary heart disease [11].
Despite progress made related to the study of IGR 
and T2DM [23], the understanding of the mechanisms 
underlying these metabolic disorders remains not fully 
clarified. Feasible biomarkers are necessary to better 
assess the risk of disease, monitor responses to treat-
ment, personalize therapy and improve patient quality 
of life implying new strategies to prevent the progress 
from IGR to T2DM.
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In this study, we sought to determine whether levels 
of four key circulating miRNAs, previously identified to 
be important for metabolic derangements, would 
change in response to a lifestyle intervention of indivi-
duals with IGR. We analysed circulating miRNA in 
serum where they are resistant to degradation; this 
resistance occurs as they are transported by carrier 
molecules including lipoproteins such as HDL, argo-
naute-2 and exosomes, which confer to miRNA high 
stability; therefore, they can be readily detected in 
blood samples [7,24]. Additionally, we tested for asso-
ciations with these miRNAs and clinical variables 
[weight, Body Mass Index (BMI), indicators of glucose 
regulation] and target genes associated with IGR and 
T2DM. For mRNA expression, our interest was to 
analyse the direct effect of the intervention in fat tissue, 
as adipose lipid mobilization through fat cell lipolysis is 
particularly interesting due to its close association with 
body fat mass and central role in energy metabo-
lism [25].
Methods
MiRNAs extraction and analysis
Serum was collected from 20 IGR individuals (n = 10 
males – mean age 61.5 ± 4.83; n = 10 females – mean 
age 60.2 ± 2.73), at baseline and following a 6-month 
telephone-led lifestyle intervention (Care Call 
Programme) where they received exercise and nutritional 
advice. The complete description of samples collecting 
and CareCall Programme details were described before 
by our group [26]. The 20 individuals were recruited in 
the time frame available, and all agreed to donate blood 
sample and adipose tissue punch in two time points, 
baseline (before starting the CareCall Programme) and 
6 months after the lifestyle intervention.
Circulating miRNAs were extracted from 500uL of 
serum pre- and post-intervention by pre-incubation 
with Trizol LS reagent (ThermoFisher Scientific) fol-
lowed by purification using RNeasy Mini Kit (Qiagen- 
UK), and 2uL was reverse transcribed using TaqMan™ 
Advanced miRNA cDNA Synthesis Kit (ThermoFisher 
Scientific) generating a total of 20uL of cDNA, follow-
ing the manufacturer’s instructions. The levels of four 
key miRNAs (Let-7a, Let-7e, miR-144 and miR-92a) 
previously shown to be associated with diabetes 
[4,16,18,19,21,27–30] were analysed by RT-qPCR on 
a StepOne machine (Applied Biosystems), using the 
TaqMan™ Advanced miRNA assays (477827_mir, 
478575_mir, 477914_mir, 477860_mir, 478579_mir) 
and TaqMan Fast advanced mastermix (ThermoFisher 
Scientific). The experiments were performed in 
triplicates in a total volume of 15 μL containing 5 μL 
of cDNA template, 10 μL of TaqMan Fast advanced 
master mix, 1 μL of miRNA assay and 4 μL of RNase- 
free water per reaction. The thermal-cycling conditions 
were performed as follows: enzyme activation step at 
95ºC, 20 sec, 1 cycle; denaturation step at 95ºC, 1 sec, 
40 cycles; annealing/extension step at 60ºC, 20 sec, 40 
cycles. Cq values higher than the cut-off of 38 were not 
considered as a reliable expression value, according to 
MIQE Guideline [31], and therefore were excluded 
from the statistical analysis.
MiR-16 was previously reported to have relatively 
stable expression across most human tissues, including 
plasma and serum [32–34] and was used as an endo-
genous control.
This study was submitted to the Ethics committee of 
Research and Development Department of Salford 
Royal NHS Foundation Trust and the permission was 
granted in accordance with the Research Governance 
Framework (2005), Medicines for Human Uses 
(Clinical Trials) Regulations (2004) and Salford Royal 
NHS Foundation Trust local policies (proc number 14/ 
NW/1196).
All the following experiments for miRNAs and gene 
expression were conducted in a blind way to reduce or 
eliminate experimental biases. KS participated in the 
recruitment of IGR participants, sample collection and 
labelling. HAF and CML conducted all the molecular 
biology experiments.
RNA extraction and gene expression analysis
All IGR participants had a punch of subcutaneous fat 
tissue collected for RNA extraction. The adipose tissue 
was taken from a gluteal fat biopsy. A small area 
around the upper buttock was anaesthetized with 
a local anaesthetic. A sample of superficial fat, measur-
ing approximately 5 mm diameter by 5 mm deep, was 
taken with a punch biopsy needle. The skin was sutured 
with one or two stitches and a sterile dressing applied 
afterwards. The participant was asked to come back to 
the Clinical Research Facility (CRF) after one week for 
suture removal. The next study visit appointment was 
given and the participant discharged from CRF. RNA 
was extracted using AllPrep DNA/RNA Mini Kit 
(Qiagen, Valencia, CA). Gene expression analyses 
were conducted for 18 genes in fat tissue (PPARG, 
GIPR, IGF2BP2, FTO, CAV1, IGF1 R, INSR, IGFBP4, 
WFS1, IGF1, LPL, IGFBP2, IGF2, IGFBP6, LEP, LDLR, 
IGFR2, HHEX), known to be implicated in the modula-
tion of weight change and interventions as diet and 
exercise, impaired glucose regulation and T2DM. The 
viability and quantity of the RNA were determined by 
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NanoDrop® ND-1000 spectrophotometer (Nanodrop, 
Wilmington, DE). High-capacity cDNA Reverse 
Transcription Kit (Life Technologies, Foster City, CA) 
was used to synthesize cDNA by using approximately 
400 ng of each RNA sample, and 50 ng of cDNA were 
then diluted in H2O mixed with TaqMan® Universal 
PCR Master Mix (Life Technologies) and disposed in 
a 96 well plate.
Relative gene expression was determined using 
a LightCycler 480 machine (Roche) running LightCycler 
480 SW 1.5.0 SP3 software. The assays used in this study 
were Roche RealTime ready single assays (PPARG, GIPR, 
IGF2BP2, FTO, CAV1, IGF1 R, INSR, IGFBP4, WFS1, 
IGF1, LPL, IGFBP2, IGF2, IGFBP6, LEP, LDLR, IGFR2, 
HHEX) relative to two housekeeping genes (ACTB and 
RN18S1). All genes were assayed in triplicate and 50 ng of 
total cDNA was used per reaction for all. The qPCR 
protocol was as follows: pre-incubation – 1 cycle at 95°C 
for 10 minutes, amplification – 50 cycles at 95°C for 10 
secs, 60°C for 30 secs and 72°C for 1 sec, cooling – 1 cycle, 
40°C for 30 secs.
We quantified the gene expression using the 
Comparative threshold (Ct) method (ΔΔCt Method) 
[35,36], and the amount of target gene was normalized 
to ACTB as housekeeping gene (as it was stable across 
all samples, p > 0.05) and determined by 2−ΔΔCt, as 
previously described [37,38], with relative expression 
levels reported as fold change. Cq values higher than 
the cut-off of 35 were not considered as a reliable 
expression value, according to the manufacturer’s 
recommendations, and therefore were excluded from 
the statistical analysis. The expression of target mRNAs 
was then correlated with the miRNAs levels in consid-
ered important pathways to the development of T2DM.
Statistical analysis
All analyses were carried out using Statistical Package 
for Social Sciences (SPSS version 20.0, Armonk, NY, 
USA). Cq values of miRNA levels were expressed as 
2−ΔCq [39]. Descriptive analyses were performed to 
evaluate socio-demographic and clinical characteristics. 
We have performed a general linear model as a first 
analysis considering the clinical variables and miRNAs 
as dependent variables, weight change categories as 
fixed factor, adjusting for age and sex. Changes in 
miRNA levels before and after intervention were com-
pared by Paired T-test followed by Bonferroni correc-
tion for multiple comparisons as a post-hoc test and 
considered significant when p ≤ 0.025. The miRNA 
levels were then correlated with clinical parameters 
and mRNA expression by Pearson’s correlation consid-
ering r ≥ 0.35 and p ≤ 0.05 significant. As we did not 
see any effect of age and sex for any of the variables, pre 
and post intervention, we carried out our correlations 
without age and sex adjustment. The data were corre-
lated using Displayr and presented as correlation 
matrix. We performed the Kolmogorov–Smirnov test, 
and all the variables presented normal distribution 
(p > 0.05); thus, we performed parametric tests for 
our analysis.
Results
Socio-demographic and clinical characteristics of 
the sample
All individuals completed the study. At the end of 
6 months of lifestyle intervention, the majority of the 
patients maintained (45%) or lost 3% (40%) in weight 
or more. Only three (15%) of patients gained weight. 
We analysed the changes in clinical variables of all 
patients together and separately for those who main-
tained the same weight or lost weight. The socio- 
demographic and clinical characteristics of all IGR 
patients included in this study and considering only 
those who maintained or lost 3% of weight or more 
(85% in total) are shown in Table 1.
Circulating MiRNA expression changes before and 
after the lifestyle intervention
The expression of miR-16 was stable across all our sam-
ples (t = −1.05, p = 0.303) and used as endogenous con-
trol. In the whole cohort (n = 20) both Let-7a and miR- 
92a were significantly higher following the intervention 
(for Let-7a: t = −2.91, p = 0.009; and for miR-92a: 
t = −4.71, p = 0.0001) (Figure 1a), while Let-7e and 
miR-144 did not show changes after the intervention 
(t = 1.34, p = 0.196 and t = −0.780, p = 0.445, respectively). 
When we analysed those people who maintained or lost 
weight only (n = 17) over the 6-month intervention, miR- 
92a and Let-7a remained elevated post-intervention, how-
ever only miR-92a achieving statistical significance 
(t = −3.73, p = 0.008 for miR-92a and t = −2.14, 
p = 0.048 for let-7a) (Figure 2). In this group however 
Let-7e levels were significantly decreased post- 
intervention (t = 2.09, p = 0.017) (Figure 1b).
Gene expression in fat tissue of IGR patients
The results related to gene expression were reported pre-
viously by our group [40]. Summarizing, from the panel 
of genes chosen to be analysed, we found that the lifestyle 
intervention in IGR patients only reduced the expression 
of CAV1 with no changes in any other target genes (data 
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not shown). We also did not find differences when 
excluding patients who gain weight after the intervention. 
For this reason, we tested the results of all IGR patients for 
correlations with miRNAs. Following the Cq cut off we 
excluded two patients from the mRNA analysis.
Correlations between miRNA levels, clinical 
variables and target genes
We tested by Pearson’s correlation the baseline and 
post-intervention miRNA levels and clinical variables 
of all IGR individuals and separately those who main-
tained or lost 3% in weight or more, as we found 
different results in miRNA levels when considering all 
patients and separately excluding those who gain 
weight. Considering all IGR individuals we found sig-
nificant negative correlations at baseline between Let-7a 
and triglycerides (r = −0.526, p = 0.025) and miR-144 
and cholesterol (r = −464, p = 0.039) (Figure 2a). Post- 
intervention we found positive correlations between 
Let-7e and insulin (r = 454, p = 0.044), miR-92a and 
weight (r = 0.471, p = 0.036) and BMI (r = 0.544, 
p = 0.013), and a negative correlation between miR- 
92a and HDL (r = −0.449, p = 0.047) (Figure 2b).
Excluding the individuals who gained weight, all the 
correlations we found before were maintained, however 
showing stronger significance. When baseline miRNA 
levels were correlated with clinical parameters we found 
significant negative correlations between Let-7a and 
triglycerides (r = −0.588, p = 0.021) and between 
miR-144 and cholesterol (r = −0.491, p = 0.045) 
(Figure 3a). After the intervention we found positive 
correlations between Let-7e and insulin (r = 0.551, 
p = 0.022) and miR-92a and BMI (r = 0.556, 
Table 1. Anthropometric measurements and clinical variables 
of IGR participants before and after the intervention.
Before 
(Mean ± SD)
After 
(Mean ± SD)
p Value 
*≤0.025
All IGR participants (n = 20)
Age (y) 60.85 (12.1)
Weight (kg) 101.5 (23.9) 99.2 (24.7) 0.025*
Height (cm) 168.85 (10.8)
BMI 35.66 (7.6) 34.86 (7.9) 0.023*
Waist-hip 0.953 (0.08) 0.950 (0.07) 0.763
HDL (mmol/L) 1.37 (0.71) 1.30 (0.38) 0.685
LDL (mmol/L) 2.75 (1.01) 2.66 (1.04) 0.593
Triglycerides (mmol/L) 1.5 (0.79) 1.62 (0.70) 0.464
Insulin (pmol/L) 190.80 (259.9) 270.93 (588.4) 0.482
Total cholesterol 4.69 (1.20) 4.83 (1.11) 0.328
HOMA-S 68.4 (42.59) 74.64 (56.86) 0.757
HOMA-B 134.35 (62.24) 113.93 (39.22) 0.078
FPG 5.58 (0.87) 5.90 (1.25) 0.149
HbA1 c 44.55 (2.52) 45.11 (10.99) 0.820
Patients maintained or lost 3% or more in weight (n = 17)
Weight (kg) 100.6 (24.5) 97.2 (24.8) 0.001*
BMI 35.5 (7.48) 34.2 (7.71) 0.001*
Waist-hip 0.95 (0.09) 0.95 (0.07) 0.726
HDL (mmol/L) 1.36 (0.77) 1.28 (0.40) 0.691
LDL (mmol/L) 2.75 (1.09) 2.52 (1.12) 0.232
Triglycerides (mmol/L) 1.55 (0.85) 1.62 (0.76) 0.697
Insulin (pmol/L) 207.84 (279.20) 301.55 (635.87) 0.487
Total cholesterol 4.69 (1.28) 4.74 (1.18) 0.741
HOMA-S 73.28 (44.79) 75.84 (60.47) 0.913
HOMA-B 126.35 (51.71) 111.87 (36.41) 0.236
FPG 5.50 (0.87) 5.28 (0.43) 0.369
HbA1 c 43.57 (1.39) 39.42 (1.51) 0.006*
*p values refer to paired T-test analysis of measures at baseline and after 
the lifestyle intervention. BMI: body mass index; HDL: high-density lipo-
protein cholesterol; LDL: low-density lipoprotein cholesterol; HOMA- 
S: Homoeostasis Model Assessment insulin sensitivity; HOMA- 
B: Homoeostasis Model Assessment beta-cell function; FPG: fasting 
plasma glucose; HbA1c: glycated haemoglobin. 
Figure 1. (a) MicroRNAs expression in serum of IGR individuals 
(n = 20) at baseline and 6 months after the lifestyle interven-
tion. Data were analysed by Paired T-test and are expressed as 
Mean ± SD (p ≤ 0.025). (b) MicroRNAs expression in serum of 
IGR individuals which maintained weight or lost 3% of weight 
only (n = 17) at baseline and 6 months after the lifestyle 
intervention. Data were analysed by Paired T-test and are 
expressed as Mean ± SD (p ≤ 0.025).
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p = 0.021), also negative correlation between miR-92a 
and HDL (r = −0.619, p = 0.008) (Figure 3b).
Regarding the target genes and miRNAs correlations, 
considering all IGR individuals, when analysed at base-
line we found positive correlations between Let-7a and 
INSR (r = 0.526, p = 0.025), Let-7e and IGF1 R (r = 0.474, 
p = 0.047), miR-144 and FTO (r = 0.508, p = 0.031) and 
miR-92a and FTO (r = 0.545, p = 0.019) (Figure 4a). After 
the lifestyle intervention we found positive correlations 
between Let-7e and PPARG (r = 0.599, p = 0.009), miR- 
144 and IGF2BP2 (r = 0.779, p < 0.0001), and negative 
correlations between miR-92a and IGFBP4 (r = −0.509, 
p = 0.031), IGF2 (r = −0.559, p = 0.016) and IGFBP6 
(r = −0.706, p = 0.001) (Figure 4b).
Discussion
Multiple mechanisms are involved in the pathology of 
T2DM including inflammatory response, abnormal 
insulin secretion and glucose metabolism, and many 
aspects still require elucidation [10,12,22]. 
Improvements of our knowledge in the mechanisms 
a 
b 
Figure 2. (a) Correlation matrix among microRNAs and clinical variables in all IGR individuals at baseline. Analysis were done by 
Pearson’s correlation, p ≤ 0.05. The r values for each correlation are shown in the squares. (b) Correlation matrix among microRNAs 
and clinical variables in all IGR individuals post-intervention. Analysis were done by Pearson’s correlation, p ≤ 0.05. The r values for 
each correlation are shown in the squares.
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overlapping genetic and epigenetic aspects in T2DM 
may help to drive future research towards an integrated 
pathophysiological approach and to provide future 
directions in the field.
Although miRNAs have been investigated in T2DM 
and impaired glucose tolerance status, to the best of our 
knowledge, this is the first time that changes in 
miRNAs levels have been investigated in patients with 
IGR considering two time points: before (baseline) and 
6 months after a telephone-based lifestyle intervention 
involving diet and exercise. The lifestyle intervention in 
patients with IGR sought to improve their dietary and 
exercise habits; after 6 months, it resulted in changes in 
miRNAs in general and linked to weight loss. Our 
results showed increased levels of Let-7a and miR-92a 
in all individuals submitted to the intervention while 
decreased levels of Let-7e were observed only in those 
who maintained or lost weight. The intervention also 
caused miR-92a and Let-7a upregulation linked to 
weight loss. Additionally, we found several correlations 
a 
b 
Figure 3. (a) Correlation matrix among microRNAs and clinical variables in IGR individuals who maintained or lost 3% in weight or 
more at baseline. Analysis were done by Pearson’s correlation, p ≤ 0.05. The r values for each correlation are shown in the squares. 
(b) Correlation matrix among microRNAs and clinical variables in IGR individuals who maintained or lost 3% in weight or more post- 
intervention. Analysis were done by Pearson’s correlation, p ≤ 0.05. The r values for each correlation are shown in the squares.
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at both points (baseline and after 6 months of the 
lifestyle intervention) between the miRNAs and circu-
lating lipids, BMI/weight, and with gene expression for 
genes involved in glucose regulation and T2DM.
Let-7 is a miRNA fundamental in suppressing tumour 
cell proliferation, conserved across diverse animal species 
from flies to humans [41]. Despite the fact that the biolo-
gical functions of Let-7 have not been well investigated 
and show contradictory results, decreased levels of Let-7 
miRNAs are normally associated with poor prognosis 
[42]. It was demonstrated before that Let-7a was down-
regulated in patients with IGR compared to normoglyce-
mic individuals and considered a predictor of IGR [4]. 
Also, its overexpression was able to prevent cell death and 
attenuated pro-inflammatory response in the brain 
endothelial cells under high glucose conditions [16]. We 
found that after a lifestyle intervention IGR individuals 
had increased levels of Let-7a, supporting the hypothesis 
a 
b  
Figure 4. (a) Scatter plots representing the correlations among microRNAs and target genes in all IGR individuals at baseline. 
Analysis were done by Pearson’s correlation, p ≤ 0.05, r ≥ 0.350. (b) Scatter plots representing the correlations among microRNAs 
and target genes in all IGR individuals post-intervention. Analysis were done by Pearson’s correlation, p ≤ 0.05 r ≥ 0.350.
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that this miRNA has a protective role [16,41] targeting 
glucose metabolism [4]. An unexpected finding was the 
downregulation of Let-7e in those individuals who main-
tained or lost weight after the intervention. Let-7e, as part 
of Let-7 family, is known to have protective activity [41]. 
However, as mentioned above, even though members of 
the Let-7 family are widely documented as tumour sup-
pressor miRNAs, dysregulation of specific family mem-
bers in different cancer types has also been described [41]. 
Indeed, elevated Let-7e expression was significantly cor-
related with vein invasion and poor prognosis in hepato-
cellular carcinoma [28].
In our study, we found increased levels of miR-92a in 
all IGR individuals following lifestyle intervention and 
this higher expression was maintained also when we 
exclude patients who gained weight. These results suggest 
a role for this miRNA in weight modulation as we also 
observed positive associations of miR-92a with weight 
and BMI post-intervention. MiR-92a is reported to have 
a role in angiogenesis, atherosclerosis [21,30,43] and 
endothelial dysfunction [10,22]. In this regard, the levels 
of miR-92a were shown to be reduced in CD34+ cells 
from individuals with diabetic retinopathy compared 
with control subjects and patients with diabetes without 
diabetic retinopathy [20]. Interestingly, we also found 
a negative correlation between this miRNA and high- 
density lipoprotein (HDL) post-intervention, it is already 
known that HDL has a role in transporting endogenous 
miRNAs and delivering them to recipient cells with func-
tional targeting capabilities [14]. MiRNAs, specifically 
miR-92a was seen to be involved in the regulation of 
angiogenesis and transported within HDL to sites of 
injury/repair [44].
Even though we did not see variations in miR-144 as 
a consequence of the intervention, we found at baseline 
a negative correlation between miR-144 and total choles-
terol. miRNA-144 is a key miRNA in the pathological 
processes of T2DM, and is an important component of 
the insulin-signalling cascade [19] and lipid metabolism 
[45] and also strongly associated with the IGF-1 R signal-
ling pathway [46].
Recent studies have shown abnormalities of miRNAs 
linked with T2DM [10–12] and exploring the broad inter-
action among the genetic, epigenetic and environmental 
influences involved in the concomitant development of 
T2DM and CVD complications [12]. MiRNAs are known 
to regulate gene expression by inhibiting translation via 
binding to the 3′ untranslated region of their target mRNA 
[5]. So far, only few miRNAs have been linked to glucose 
metabolism and metabolic disorders [2,4]. We tested for 
associations the miRNAs analysed in this study with target 
genes known to be involved in glucose metabolism and 
T2DM. At baseline, considering the status of the patients as 
pre-diabetes, we found positive correlations between Let-7a 
and INSR, Let-7e and IGF1 R, miR-144 and FTO and miR- 
92a and FTO. It was demonstrated before that Let-7a can 
regulate the expression of INSR in breast cancer cell lines 
[47], confirming the function of this miRNA in targeting 
genes related to IGF signalling pathway [47]. Additionally, 
Let-7e was showed to be able to control IGF1 R expression 
in colorectal cancer cells [29] suggesting that Let-7e could 
be used in IGF1 R-targeted therapeutics in anticancer 
therapy. No evidence was found in the literature regarding 
associations with miR-144 and miR-92a with FTO; how-
ever, these miRNAs have been shown to be involved in 
insulin resistance [48] and diabetes [4,20].
Post-intervention, IGR patients showed an improve-
ment in β-cell function, followed by weight loss. The cor-
relations we found with miRNAs and target genes were 
mostly associated with IGF system. MiR-92a was negatively 
correlated with IGFBP4, IGFBP6 and IGF2; Let-7e was 
positively correlated with PPARG and miR-144 showed 
a positive correlation with IGFBP2. It is known that 
IGFBP6 protein can bind IGF2 and prevent the interac-
tions of this protein with other receptors, such as IGF1 R 
and INSR [47]. In our study, we found enhanced miR-92 as 
a consequence of lifestyle intervention, and this miRNA 
was shown to be negatively correlated with IGFBP6, among 
other genes involved in the IGF system (IGFBP4 and 
IGF2). If we consider that the increase of miR-92a can act 
suppressing the IGFBP6 gene post intervention, this 
mechanism could be enhancing the interaction of IGF2 
with its receptors in adipose tissue cells. These evidence 
corroborates with our previous findings with these indivi-
duals showing that higher levels of IGF2 at baseline in IGR 
patients was predictive of weight loss [26] and reinforcing 
IGF2 has an important participation in weight manage-
ment in T2DM [49]. Regarding the associations between 
Let-7e and PPARG and between miR-144 and IGFBP2, no 
previous studies were found showing such links. However, 
both genes are known to participate in the regulation of 
glucose and lipid metabolism [50–53] and our results sug-
gest they can be targets of these miRNAs.
Our study has some limitations due to the number 
of participants, even though we have strength in that 
participants consented to donate blood and fat tissue 
pre- and post-intervention, which permitted us to iden-
tify miRNA responses before and after the intervention 
and the link between miRNAs and gene expression in 
both time points. Another important limitation is the 
lack of data on menopausal status in women, which 
could influence our findings; however, the mean age 
variation in women was very small (60 ± 2.7 y old).
In conclusion, we speculate the association of 
miRNAs with insulin and the IGF system (both recep-
tors and binding proteins) could represent a method of 
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regulating the metabolic actions of IGFs, but this will 
require further experimental validation. In obesity and 
the metabolic syndrome, there is a dysregulation of IGF 
binding protein production that results in altered levels 
and action of the free fraction of IGF-I [54–56]. 
MiRNAs may be involved in that dysregulation and 
warrant further study.
A telephone-led lifestyle intervention involving dietary 
and exercise advice resulted in marked changes in several 
miRNAs and their associations with clinical variables and 
target genes shown to be associated with diabetes. Our 
results encourage the continuity of the investigation of 
how miRNAs regulate metabolic process and may be new 
targets in preventing the progress of IGR status to T2DM 
that consist of a serious health burden worldwide.
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